Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors

Environmental Health Perspectives

Volumn 111, Issue 16, 2003, Pages 1892-1901

  Olsen, Geary W ^a   Church, Timothy R ^b   Miller, John P ^c   Burris, Jean M ^a   Hansen, Kristen J ^a   Lundberg, James K ^a   Armitage, John B ^c   Herron, Ross M ^c   Medhdizadehkashi, Zahra ^c   Nobiletti, John B ^c   O'Neil, E Mary ^c   Mandel, Jeffrey H ^a   Zobel, Larry R ^a  

^a 3M COMPANY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c AMERICAN RED CROSS   (United States)

Author keywords

American Red Cross; Biomonitoring; Blood donors; Fluorochemicals; Perfluorooctane sulfonate; Perfluorooctanoate; PFOA; PFOS

Indexed keywords

PERFLUOROOCTANOIC ACID; SULFONIC ACID DERIVATIVE;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXPOSURE; FEMALE; GEOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMATION; MALE; MASS SPECTROMETRY; OBSERVATION; PRIORITY JOURNAL; RED CROSS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNITED STATES;

EID: 10744224115     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.6316     Document Type: Article

References (73)

1. M Company. 2003. Health and Environmental Assessment of Perfluorooctane Sulfonic Acid and Its Salts. U.S. EPA docket AR-226-1486. Washington, DC:U.S. Environmental Protection Agency.
2. Alexander BJ. 2001. Mortality of Workers Employed at the 3M Cottage Grove Facility. Minniapolis, MN:University of Minnesota. U.S. EPA docket AR-226-1030a18. Washington, DC:U.S. Environmental Protection Agency.
3. Alexander BJ, Olsen GW, Burris JM, Mandel JH, Mandel JS. 2003. Mortality of employees of a perfluorooctanesulfonyl fluoride manufacturing facility. Occup Environ Med 60:792-799.
4. Allen J, Butler DD. 1993. Assessing the effects of donor knowledge and perceived risk on intentions to donate blood. J Health Care Mark 13:26-33.
5. Andaleeb SS, Basu AK. 1995. Explaining blood donation: the trust factor. J Health Care Mark 15:42-48.
6. Belisle J. 1981. Organic fluorine in human serum: natural versus industrial sources. Science 212:1509-1510.
7. Berthiaume J , Wallace KB. 2002. Perfluorooctanoate, perfluorooctanesulfonate and N-ethyl perfluorooctanesulfonamide ethanol: peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett 129:23-32.
8. Biegel LB, Hurt ME, Frame SR, O'Connor JC, Cook JC. 2001. Mechanisms of extrahepatic tumor induction by peroxisome proliferators in male CD rats. Taxicol Sci 60:44-55.
9. Biegel LB, Liu RCM, Hurtt ME, Cook JC. 1995. Effects of ammonium perfluorooctanoate on Leydig cell function: in vitro, in vivo, and ex vivo studies. Toxicol Appl Pharmacol 134:18-25.
10. Burnett JJ. 1982. Examining the profiles of the donor and non-donor through a multiple discriminant approach. Transfusion 22:136-142.
11. Burris JM, Lundberg JK, Olsen GW, Simpson C, Mandel JH. 2002. Interim Report Determination of Serum Half-lives of Several Fluorochemicals. St. Paul, MN:3M Company. U.S. EPA docket AR-226-1086. Washington, DC:U.S. Environmental Protection Agency.
12. Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, et al. 2002a. Toxicity of ammonium perfluorooctanoate (APFO) in male cynomolgus monkeys after oral dosing for six months. Toxicol Sci 69:244-257.
13. Butenhoff J, York R, Seacat A, Luebker D. 2002b. Perfluorooctanesulfonate-incluced perinatal mortality in rat pups is associated with a steep dose-response [Abstract]. Toxicologist 66:25.
14. Butenhoff JL, Seacat AM. 2001. Comparative sub-chronic toxicity of perfluorooctanesulfonate (PFOS) and N-ethyl perfluorooctanesulfonamido-ethanol (N-Et FOSE) in the rat [Abstract]. Toxicologist 60:348.
15. CDC. 2003. Second National Report on Human Exposure to Environmental Chemicals. NCEH Publ. No. 02-0716. Atlanta, GA:Nationai Center for Environmental Health, Centers for Disease Control and Prevention.
16. Chiavetta J, Ennis M, Gula CA, Baker AD, Chambers TL. 2000. Test-seeking as motivation in volunteer blood donors. Transfusion Med Rev 14:205-215.
17. Cohen SM. 1998. Urinary bladder carcinogenesis. Toxicol Pathol 26:121-127.
18. Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PM. 1999. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms and relevance to humans. Crit Rev Toxicol 29:169-261.
19. Cook JC, Murray SM, Frame SR, Hurtt ME. 1992. Induction of Leydig cell adenomas by ammonium perfluorooctanoate: a possible endocrine-related mechanism. Toxicol Appl Pharmacol 113:209-217.
20. 14C-Ammonium Perfluorooctanoate in Male and Female Rats, Mice, Hamsters, and Rabbits. Newark, DE:DuPont Company. U.S. EPA docket AR-226. Washington, DC:U.S. Environmental Protection Agency.
21. Efron B, Tibshirani RJ. 1993. An introduction to the bootstrap. In: Monographs on Statistics and Applied Probability, Vol 57 (Cox DR, Hinkley DV, Reid N, Rubin DB, Silvernan BW, eds). New York:Chapman Hall, 1-177.
22. Ellefson ME. 2001. Solubility Study of Perfluorooctanesulfonate (FPFOS), SD-018 and Perfluorooctanesulfonamide (FOSA), SE-027 in Male/Female Human Urine. St. Paul, MN:3M Company. U.S. EPA docket AR-226-1030a007. Washington, DC:U.S. Environmental Protection Agency.
23. Giesy JP, Kannen K. 2001. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol 35(7):1339-1342.
24. Gilliland FD, Mandel JS. 1993. Mortality among employees of a perfluorooctanoic acid production plant. J Occup Med 35:950-954.
25. Gilliland FD, Mandel JS. 1996. Serum perfluorooctanoic acid and hepatic enzymes, lipoproteins and cholesterol: a study of occupationally exposed men. Am J Ind Med 26:560-568.
26. Grasty RC, Grey BE, Thibodeaux J, Lau C, Rogers JM. 2002. Critical period for increased neonatal mortality induced by perfluorooctane sulfonate (PFOS) in the rat [Abstract]. Toxicologist 66:25.
27. Hagen DF, Belisle J, Johnson JD, Venkateswarlu P. 1981. Characterization of fluorinated metabolites by a gas chromatographic-helium microwave plasma detector - the biotransformation of 1H,1H,2H,2H-perfluorodecanol to perfluorooctanoate. Anal Biochem 118:336-343.
28. Hanhijarvi H, Ylinen M. 1988. A proposed species difference in the renal excretion of perfluorooctanoic acid in the beagle dog and rat. In: New Developments in Biosciences: Their Implications for Laboratory Animal Sciences (Beynen A, Sollveld H, eds). Dordrecht, the Netherlands:Martinus Nijhoff, 409-412.
29. Hansen KJ, Clemen LA, Ellefson ME, Johnson HO. 2001. Compound-specific quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol 35:766-770.
30. Hansen KJ, Johnson HO, Eldridge JS, Butenhoff JL, Dick LA. 2002. Quantitative characterization of trace levels of PFOS and PFOA in the Tennessee River. Environ Sci Technol 36:1681-1685.
31. Haughom B, Spyclevold O. 1992. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta 1128:65-72.
32. Hu W, Jones PD, Upham BL, Trosko JE, Lau C, Giesy JP. 2002. Comparisons among perfluorinated compounds of effects on gap junctional intercellular communication. Toxicol Sci 68:429-436.
33. Insightful Corporation. 2001. S-Plus for Windows: Guide to Statistics, Vol 1. Seattle, WA:Insightful Corporation.
34. 14C in Rats after a Single Oral Dose. St. Paul, MN:Riker Laboratories, Inc. U.S. EPA docket AR-226-0007. Washington, DC:U.S. Environmental Protection Agency.
35. 14C]perfluorooctanesulfonate. Fundam Appl Toxicol 4:972-976.
36. 14C. St. Paul, MN:Riker Laboratories, Inc. U.S. EPA docket AR-226-0457. Washington, DC:U.S. Environmental Protection Agency.
37. Kannan K, Corsolini S, Falandysz J, Oehme G, Focardi S, Giesy JP. 2002a. Perfluorooctanesulfonate and related fluorinated hydrocarbons in marine mammals, fishes, and birds from coasts of the Baltic and Mediterranean Seas. Environ Sci Technol 36:3210-3216.
38. Kannan K, Franson JC, Bowerman WW, Hansen KJ, Jones PD, Giesy JP. 2001a. Perfluorooctanesulfonate in fish-eating water birds including bald eagles and albatrosses. Environ Sci Technol 35:3065-3070.
39. Kannan K, Koistenen J, Beckmen K, Evans T, Gorzelany JF, Hansen KJ, et al. 2001b. Accumulation of perfluorooctanesulfonate in marine mammals. Environ Sci Technol 35:1593-1598.
40. Kannan K, Newsted J, Halbrook RS, Giesy JP. 2002b. Perfluorooctanesulfonate and related fluorinated hydrocarbons in mink and river otters from the United States. Environ Sci Technol 36:2566-2571.
41. Keller B, Marsman D, Popp J, Thurman R. 1992. Several nongenotoxic carcinogens uncouple mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1102:237-244.
42. Kennedy GL, Butenhoff JL, Olsen GW, O'Connor JC, Seacat AM, Perkins RG, et al. In press. The toxicology of perfluorooctanoate. Crit Rev Toxicol.
43. Lange CS. 2001. The 18-Day Aerobic Biodegradation Study of Perfluorooctanesulfonyl-Based Chemistries. Minneapolis, MN:Pace Analytical Services, Inc. U.S. EPA docket AR-226-1030a038. Washington, DC:U.S. Environmental Protection Agency.
44. Lau C, Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Stanton ME, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II. Postnatal evaluation. Toxicol Sci 74:382-392.
45. Leibrecht BC, Hogan JM, Luz GA, Tobias KI. 1976. Donor and nondonor motivations. Transfusion 16:182-189.
46. Luebker DL, Butenhoff JL, Bass N, Hansen KJ, Seacat AM. 2002. Interactions of perfluoroalkylsulfonamides with L-FABP and BSA in vitro. Toxicology 176:175-185.
47. Martin JW, Buir DCK, Moody CA, Ellis DA, Kwan WC, Solomon KR, et al. 2002. Collection of airborne fluorinated organics and analysis by gas chromatography/chemical ionization mass spectrometry. Anal Chem 74:584-590.
48. Obourn JO, Frame SR, Bell RH, Longnecker DS, Elliott GS, Cook JC. 1997. Mechanisms for the pancreatic oncogenic effects of the peroxisome proliferator Wyeth-14,634. Toxicol Appl Pharmacol 145:425-436.
49. O'Brien TM, Wallace KB. 2002. Structural determinant of perfluorooctyl-derivative-modiated induction of the mitochondrial permeability [Abstract]. Toxicologist 66:362.
50. OECD (Organisation for Economic Co-operation and Development). 2002. Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts. U.S. EPA docket AR-226-1140. Available: http://www.oecd.org/dataoecd/23/18/238288O.pdf [accessed 8 October 2003].
51. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2000. Plasma cholacystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. Drug Chem Toxicol 23:603-620.
52. Olsen GW, Burris JM, Burlew MM, Mandel JH. 2003a. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoete [PFOA) concentrations and medical surveillance examinetons. J Occup Environ Med 45:260-270.
53. Olsen GW, Burris JM, Mandel JH, Zobel LR. 1999. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med 41:799-806.
54. Olsen GW, Gilliland FD, Burlew MM, Burris JM, Mandel JS, Mandel JH. 1998. An opidemiologic investigation of reproductive hormones in men with occupational exposure to perfluorooctanoic acid. J Occup Environ Med 40:614-622.
55. Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. 2003b. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol 37:888-891.
56. Olsen GW, Logan PW, Hansen KJ, Simpson CA, Burris JM, Burlew MM, et al. 2003c. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site: biomonitoring Am Ind Hyg Assoc J 64:651-659.
57. Oswalt RM. 1977. A review of blood donor motivation and recruitment. Transfusion 17:123-135.
58. Seacat AM, Thomford PJ, Butenhoff JL. 2002a. Terminal observations in Sprague-Dawley rats after lifetime dietary exposure to potassium perfluorooctanesulfonate [Abstract]. Toxicologist 66:185.
59. Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, et al. 2002b. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183:117-131.
60. Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. 2002c. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci 68:249-264.
61. Singer L, Ophaug RH. 1979. Concentrations of ionic, total, and bound fluoride in plasma. Clin Chem 25:523-525.
62. Starkov A, Wallace KB. 2002. Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol Sci 66:244-252.
63. Tandem Labs. 1999. Quantitative Determination of PFOS, PFOSA, PFOSAA, N-MeFOSE-OH, N-EtFOSE, POAA, and PFHS in Human Serum by LC/MS/MS. Assay Revalidation Report. Report No. NWBROO-005. Salt Lake City, UT:NWT Inc. U.S. EPA docket AR-226-1208. Washington, DC:U.S. Environmental Protection Agency.
64. Tandem Labs. 2001a. Quantitative Determination of PFOS, PFOSA, PFOSAA,POAA, PFHS, M556 and M570 in Human Serum by LC/MS/MS. Assay Revalidation Report Report No. NWBR00-108. Salt Lake City, UT:NWT Inc. U.S. EPA docket AR-226 1209. Washington, DC:U.S. Environmental Protection Agency.
65. Tandem Labs. 2001b. Quantitative Determination of PFOS, PFOSA, PFOSAA, POAA, PFHS, M556 and M570 in Human Serum by LC/MS/MS. Assay Revalidation Addendum Report. Report No. NWBR00-122. Salt Lake City, UT:NWT Inc. U.S. EPA docket AR-226-1210. Washington, DC:U.S. Environmental Protection Agency.
66. Tandem Labs. 2002. Quantitative Determination of PFOS and Related Compounds in Human Serum by LC/MS/MS. Report No. NWBR01-066. Salt Lake City, UT:NWT Inc. U.S. EPA docket AR-226-1212. Washington, DC:U.S. Environmental Protection Agency.
67. Taves D. 1968. Evidence that there are two forms of fluoride in human serum. Nature 217:1050-1051.
68. Taves D, Guy W, Brey W. 1976. Organic fluorocarbons in human plasma: prevalence and characterization. In: Biochemistry Involving Carbon-Fluorine Bonds (Filler R, ed). Washington DC:American Chemical Society, 117-134.
69. Thibodeaux JR, Hanson RG, Rogers JM, Grey BE, Barbee BD, Richards JH, et al. 2003. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: Maternal and prenatal evaluations. Toxicol Sci 74:369-381.
70. Thomford PJ, Seacat AM, Butenhoff JL. 2002. Terminal observetions in Sprague-Dawley rats after lifetime dietary exposure to N-ethyl perfluorooctanesulfonamido ethanol [Abstract]. Toxicologist 66:185.
71. U.S. EPA. 2002. Perfluoroalkyl sulfonates: significant new use rule; final rule. Fed Reg 87:72854-72867.
72. Wendling L. 2003. Environmental health and safety measures relating to perfluorooctanoic acid and its salts (PFOA). 3M correspondence to US EPA Office of Prevention, Pesticides and Toxic Substances. U.S. EPA docket AR-226-1303. Washington, DC:U.S. Environmental Protection Agency.
73. Wood EM, Kim DM, Miller JP. 2001. Accuracy of pro-donation Hct sampling affects donor safety, eligibility and deferral rates. Transfusion 41:353-359.